SOURCE: BIOLASE Technology, Inc.

BIOLASE Technology, Inc.

July 25, 2011 09:00 ET

BIOLASE Reports First Orders for the BIOLASE DaVinci Imaging™ Systems for Delivery in Q-3

Further Step in Implementation of BIOLASE's Total Technology Solution™ Plan

IRVINE, CA--(Marketwire - Jul 25, 2011) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that the Company is now taking orders for its new state-of-the-art BIOLASE DaVinci Imaging™ dental imaging devices for delivery in Q-3. The diagnostic capabilities of the BIOLASE DaVinci Imaging products complement the biological, minimally invasive dental treatment solutions offered by the BIOLASE Laser division.

Chairman and CEO Federico Pignatelli said, "We are pleased to have executed our launch into this exciting new market. The dental digital imaging capital equipment market is a perfect complement to our laser devices and is the next logical step in offering a Total Technology Solution™. It allows us to leverage our established customer base of approximately 8,000 dental practices in the US and 3,000 worldwide and the recognition of the BIOLASE brand that has become synonymous with high tech dentistry over the years. BIOLASE now commands an approximate 80 percent brand recognition among US and Canada dental offices. We have been working to develop and implement a commercial plan that takes advantage of our core competencies and highlights the talents of our growing sales force that includes some of the top dental equipment sales professionals, while expanding our market coverage into key dental specialties including oral and maxillofacial surgery. We are now the only company to offer a complete product line of cutting edge dental lasers and digital imaging products."

During the past six months, BIOLASE has been expanding its sales force, with sales representatives that have extensive experience in selling imaging equipment. In addition, a select group of BIOLASE field service engineers have been trained on the installation and service of these products in anticipation of shipments in the third quarter.

"We expect the BIOLASE DaVinci Imaging division to be a substantial contributor in revenue growth and profitability going forward," Pignatelli added.

BIOLASE DaVinci Imaging products range in price from $3,000 to $125,000, and include the D3D™ 3D Cone Beam Computed Tomography (CBCT) system, iTab ™ portable digital x-ray viewer, iView™ intra-oral camera, iSensor™ digital x-ray sensors and iGen™ x-ray generator.

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's leading Dental Laser company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on laser and Waterlase dentistry, find BIOLASE at, Twitter at, and YouTube at

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:
    Jill Bertotti
    Allen & Caron